In the fight against DIPG, every child leaves an indelible mark. In the United States, Spain, and Australia, tissue banks and data centers are essential for advancing our understanding of this devastating disease and developing treatments that will one day lead to a cure.

Diffuse Intrinsic Pontine Glioma (DIPG) is a pediatric brain tumor that is difficult to access surgically, which has presented a significant challenge for the diagnosis and treatment of this disease. Traditionally, the only way to obtain genetic information from the tumor has been through conventional biopsies, an invasive procedure that, in the case of DIPG, can involve a high risk due to its location in the brainstem, a highly sensitive region vital for functions such as breathing and movement.

Given this scenario, liquid biopsy emerges as a revolutionary and safe alternative. Through the analysis of biological fluids such as cerebrospinal fluid (CSF) and blood, it is possible to obtain molecular information about the tumor without resorting to high-risk surgical procedures. This allows for:

✅ Identifying specific DIPG mutations, such as the H3K27M mutation, facilitating a precise and personalized diagnosis.
✅ Monitoring tumor evolution and treatment response in real time, without the need to repeat invasive procedures.
✅ Reducing risks and complications for patients, offering a less aggressive and more accessible option for tumor analysis.

In a context where every advance counts, liquid biopsy is positioned as a key tool for DIPG research and treatment, providing valuable information safely and effectively.